NN 8209

Drug Profile

NN 8209

Alternative Names: Anti-C5aR-151; NN-8209; NNC 0151; NNC 0151-0000-0000

Latest Information Update: 05 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Argos Therapeutics Inc
  • Developer Novo Nordisk
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Complement C5a receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 30 Sep 2013 Discontinued - Phase-I for Autoimmune disorders (In volunteers) in Netherlands (Parenteral)
  • 30 Sep 2013 Discontinued - Phase-II for Rheumatoid arthritis in Denmark, Czech Republic, Poland, Romania, United Kingdom and Hungary (SC)
  • 11 Feb 2013 Novo Nordisk completes a phase II trial in Rheumatoid arthritis in European Union (NCT01223911)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top